Biopsies and Polyps
Background: Nasal polyps are found in about 5% of asthmatic patients.A close link exists between the upper and lower airways and the concept of the "United Airways" has emerged mainly from studies on allergic rhinitis and asthma. However, other upper airway diseases, such as chronic sinusitis and nasal polyposis may influence lower airway diseases. As for nasal polyposis, eosinophils are the major effector cells in asthma and have been associated with a worsening of this condition.
Aim: To compare normal nasal mucosa and nasal polyp biopsies from subjects with nasal polyposis with or without asthma.
Hypothesis: Nasal polyps from asthmatic subjects show a more aggressive pro-inflammatory pattern of cytokine expression compared to nasal polyps from non asthmatic subjects, and therefore contribute to the development and severity of asthma.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Nasal Features of Subjects With Nasal Polyposis With or Without Asthma|
- The primary endpoint will be the difference in expression of IL-5 in nasal polyps and normal mucosa biopsies from asthmatic and non asthmatic subjects. [ Time Frame: No time frame ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Nasal polyps (Biopsies) Normal nasal mucosa (Biopsies) Sputum
|Study Start Date:||July 2007|
|Study Completion Date:||September 2009|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
Asthmatics with polyps
Non-asthmatics with polyps
The study will include 2 visits separated by a maximum of 7 days. During the first visit, subjects' characteristics will be documented by a locally validated questionnaire. Allergy skin prick tests, spirometry, methacholine inhalation test and induced sputum will also be done. Asthma and rhinitis control will be evaluated by locally validated questionnaires, the Asthma Control Scoring System (ACSS) and the Rhinitis Control Scoring System (RCSS), respectively. Nasal peak inspiratory flow (NPIF) and oral peak expiratory flow (PEF) will also be recorded to obtain the nasal blockage index (NBI). On the second visit, nasal biopsies will be taken.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00835445
|Ste-Foy, Quebec, Canada, G1V 4G5|
|Principal Investigator:||Louis-Philippe Boulet, MD||Centre de recherche, Hôpital Laval|